Epizyme Testing New Mesothelioma Treatment with Phase Two Clinical Trial
Biopharmaceutical company Epizyme, Inc. is starting a new phase two clinical trial using tazemetostat as a treatment for mesothelioma cancer.
Category: bap1
Protein Helps Doctors Diagnose Mesothelioma More Accurately
Researchers identified another tool for diagnosing pleural mesothelioma, hoping it can accelerate the diagnostic process and help eliminate recurring mistakes. Dr. Michele Carbone of the University of Hawaii Cancer Center and his team of mesothelioma specialists discovered that tumor-suppressing protein BAP1 can help oncologists accurately differentiate mesothelioma from lung cancer. People lacking the BAP1 protein…
The post Protein Helps Doctors Diagnose Mesothelioma More Accurately appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
Protein Helps Doctors Diagnose Mesothelioma More Accurately
Researchers identified another tool for diagnosing pleural mesothelioma, hoping it can accelerate the diagnostic process and help eliminate recurring mistakes. Dr. Michele Carbone of the University of Hawaii Cancer Center and his team of mesothelioma specialists discovered that tumor-suppressing protein BAP1 can help oncologists accurately differentiate mesothelioma from lung cancer. People lacking the BAP1 protein…
The post Protein Helps Doctors Diagnose Mesothelioma More Accurately appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.